Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

0 Views· 07/03/23
OncLive® On Air
OncLive® On Air
0 Subscribers
0
In Drama

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.

Show more

 0 Comments sort   Sort By


Up next